Editorial: Editor's feature: negative findings in pharmacogenetics and pharmacogenomics

José A G Agúndez; Pedro Ayuso; Luis A Quiñones; Elena García-Martín

doi:10.3389/fphar.2023.1267344

Editorial: Editor's feature: negative findings in pharmacogenetics and pharmacogenomics

Front Pharmacol. 2023 Aug 8:14:1267344. doi: 10.3389/fphar.2023.1267344. eCollection 2023.

Authors

José A G Agúndez¹, Pedro Ayuso¹, Luis A Quiñones^{2

3}, Elena García-Martín¹

Affiliations

¹ Institute of Molecular Pathology Biomarkers, University of Extremadura, Cáceres, Spain.
² Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic-Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile.
³ Latin American Network for Implementation and Validation of Clinical Pharmacogenomic Guidelines (RELIVAFCYTED), Santiago, Chile.

No abstract available

Keywords: DNA sequencing; adverse drug effects; genome-wide association studies (GWAS); genotyping; negative findings; pharmacogenomics (PGx); pharmacokinetics and drug metabolism (PDM).

Publication types

Editorial